(The JAMA Network Journals) Androgen deprivation therapy is a mainstay of prostate cancer treatment. ADT has shown survival benefit in some patients but it also has been associated with some adverse health effects and a possible link to neurocognitive dysfunction.
Prostate cancer patients who receive high-dose radiation therapy (HDRT) followed by a longer period of hormone suppression therapy, or androgen deprivation therapy (ADT), have higher five-year biochemical, disease-free survival (bDF...
Reducing testosterone levels with androgen deprivation therapy, or A.D.T., more than doubles the risk of dementia.
Men treated with androgen deprivation therapy - a hormone therapy - for prostate cancer may be more than twice as likely to develop dementia, study finds.
Androgen Deprivation Therapy, a common hormone therapy to treat prostate cancer, may double a man's risk of dementia, regardless of his age, Penn Medicine researchers reported.